/East Asia Pharmaceutical's First Extraordinary General Meeting of Shareholders in 2025 Meeting Materials

NEWS

East Asia Pharmaceutical's First Extraordinary General Meeting of Shareholders in 2025 Meeting Materials

Shanghai Stock Exchange

2025/12/20

Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials Securities Code: 605177 Securities Abbreviation: East Asia Pharmaceutical Bond Code: 111015 Bond Abbreviation: East Asia Convertible Bonds

Zhejiang East Asia Pharmaceutical Co., Ltd.

The first extraordinary general meeting of shareholders of the year

2025

Conference materials

December 2025

Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

........................................................................24

Proposal 4.10: ............................................................25 Proposal on amending the company's "Remuneration Management System for Directors, Supervisors and Senior Management Personnel"......25 Proposal 4.11:............................................................26 Proposal on amending the company's "Accounting Firm Selection System"......................26 Proposal 4.12:......................................................33 Proposal on formulating the company's "Implementation Rules for Online Voting of Shareholders' Meetings"......................33 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Instructions for the First Extraordinary General Meeting of Shareholders of the Year

2025

In order to safeguard the legitimate rights and interests of investors and ensure that shareholders can exercise their rights in accordance with the law during this general meeting of shareholders, in accordance with the "Company Law", the China Securities Regulatory Commission's "Rules for Shareholders' Meetings of Listed Companies" and the company's "Rules of Procedure for Shareholders' Meetings" and other relevant regulations, the instructions for this meeting are hereby formulated:

The company is responsible for the agenda arrangement and meeting affairs of this shareholders' meeting. Those attending the meeting should follow the arrangements of the company's staff and jointly maintain the order of the meeting.
In order to ensure the normal order of the shareholders' meeting, the company has the right to refuse entry to the venue except for shareholders or shareholders' agents, directors, supervisors, board secretaries, other senior managers, witness lawyers, personnel related to the agenda of this meeting and meeting staff who are present at the meeting. The company will stop any behavior that affects the order of the general meeting of shareholders and damages the legitimate rights and interests of other shareholders in accordance with regulations.
Shareholders and shareholders’ agents attending the general meeting of shareholders should present their ID cards or copies of business licenses, power of attorney, securities account cards and other documents to sign in according to the registration time notified by the general meeting of shareholders. Registration for the meeting shall be terminated before the host of the general meeting announces the number of shareholders and shareholders’ agents attending the meeting on site and the total number of shares with voting rights held. In principle, shareholders who have not signed in and registered cannot participate in this shareholders' meeting.
Shareholders participating in the meeting shall enjoy various rights including the right to speak, the right to question, and the right to vote in accordance with the law. Shareholders should conscientiously perform their legal obligations, consciously abide by the discipline of the meeting, and shall not affect the normal procedures or order of the meeting, nor infringe upon the rights and interests of other shareholders. The topic of shareholders' speeches should be related to the voting matters of this annual general meeting of shareholders. Questions that have nothing to do with the topics of this annual general meeting of shareholders or will reveal the company's business secrets, or will obviously harm the common interests of the company or shareholders, the host of the meeting or relevant personnel have the right to refuse to answer.
At this general meeting of shareholders, two shareholder representatives, one supervisor representative and two witnessing lawyers will participate in the counting and supervision of the voting and counting process, and the moderator will announce the voting results.
All persons attending the meeting are asked to set their mobile phones to vibrate or turn them off. Individual recording, photography and video recording are prohibited.

Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Agenda for the first extraordinary general meeting of shareholders of the year

2025

Convening time: December 25, 2025 (Thursday) 13:00

Venue: Conference Room 5, 2nd Floor, No. 21 Donghai Fifth Avenue, Taizhou Bay Economic and Technological Development Zone, Linhai City, Zhejiang Province

Mode of convening: On-site combined with the Internet

Convener: Board of Directors

Moderator: Mr. Chi Cheng, Chairman and General Manager

Participants: shareholders registered on the equity registration date or their authorized representatives, all directors, supervisors, board secretaries, and witnessing lawyers attended the meeting, and some senior managers attended the meeting.

Meeting agenda:

1. The host announces the start of the meeting;

2. Introduce the meeting agenda and meeting instructions;

Report the number of shareholders and shareholders’ proxies present on site and the number of voting shares they represent;
Introduce the directors, supervisors, board secretaries and other senior managers attending the meeting, witnessing lawyers and other personnel;

5. Select the vote counters and scrutineers for this meeting;

6. Shareholders attending the meeting will consider the following proposals one by one:

No. Meeting content Reporter 1: Proposal on adjusting the use of R&D center construction projects in initial public offering of stock investment projects Zhou Jianbo on closing the investment project with funds raised from the issuance of convertible corporate bonds to unspecified objects and making savings

2 Zhou Jianbo’s proposal to raise funds to permanently replenish working capital

3 Proposal on canceling the company's board of supervisors, amending the "Articles of Association" and going through industrial and commercial registration Zhou Jianbo 4.00 Proposal on amending and formulating some corporate governance systems Zhou Jianbo 4.01 Proposal on amending the company's "Rules of Procedure for the Shareholders' Meeting" Zhou Jianbo 4.02 Proposal on amending the company's "Rules of Procedure for the Board of Directors" Zhou Jianbo 4.03 Proposal on amending the company's "External Guarantee Management System" Zhou Jianbo 4.04 Proposal on amending the company's "Related Transaction Decision-making System" Zhou Jianbo

Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

4.05 Proposal on amending the company's "Raised Funds Management System" Zhou Jianbo 4.06 Proposal on amending the company's "Independent Director Work System" Zhou Jianbo 4.07 Proposal on amending the company's "Cumulative Voting System Implementation Rules" Zhou Jianbo 4.08 Proposal on amending the company's "Investment Decision Management System" Zhou Jianbo

Regarding the revision of the company’s “Management System to Prevent Controlling Shareholders, Actual Controllers and Related Parties from Occupying the Company’s Funds”

4.09 Zhou Jianbo

motion

4.10 Proposal on amending the company's "Remuneration Management System for Directors, Supervisors and Senior Management Personnel" Zhou Jianbo 4.11 Proposal on amending the company's "Accounting Firm Selection and Recruitment System" Zhou Jianbo 4.12 Proposal on formulating the company's "Implementation Rules for Online Voting of Shareholders' Meetings" Zhou Jianbo

7. Shareholders speak and the company’s directors, supervisors and senior managers answer shareholders’ questions;

8. On-site voting;

9. Statistical voting results;

10. The host announces the voting results;

11. Witness the lawyer reading the legal opinion;

12. Sign the resolutions and minutes of the general meeting of shareholders;

13. The host announces the end of the meeting.

Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Zhejiang East Asia Pharmaceutical Co., Ltd.

Resolutions of the First Extraordinary General Meeting of Shareholders of the Year

2025

Motion 1:

Regarding adjustments to initial public offering stock investment projects

Proposal on the purpose of the R&D center construction project

Dear shareholders and shareholder representatives:

After the R&D center construction project in the initial public offering of shares of Zhejiang East Asia Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was completed and put into use, affected by the development of the entire pharmaceutical market, the company further adjusted its development strategic planning ideas to form a "API-centered, forward-reaching, backward-looking" The "Extension" integrated development strategy of APIs and preparations has shifted from the initial strategy of focusing on intermediates and APIs to developing new preparation products and new technologies on the basis of further consolidating the market competitiveness of intermediates and APIs, and using enzymatic processes as the entry point to lay out research and development in the field of synthetic biotechnology processes. At the same time, because the company's R&D centers Shanghai Youshou Pharmaceutical Technology Development Co., Ltd. and Hangzhou Shanli Biomedical Technology Co., Ltd. are able to undertake related R&D projects, there are many vacant areas after the R&D center construction project was put into use.

In order to improve the efficiency of the company's asset use and improve the centralized office efficiency of the company's functional personnel, combined with the actual use of the company's R&D center construction project after the completion of the project and the objective situation of the company's main R&D teams working in Shanghai and Hangzhou, the company plans to permanently adjust the building constructed by the R&D center construction project into a R&D administrative complex. The existing area for R&D will remain unchanged, and part of the building area will be simultaneously adjusted for comprehensive use by other administrative departments. R&D experimental areas and related R&D equipment will be added in a timely manner based on the actual situation of the company's R&D projects. Therefore, it is necessary to adjust the purpose of the R&D center construction project in the initial public offering stock investment project. The relevant circumstances are as follows:

1. Basic situation of funds raised through initial public offering of stocks

(1) The actual amount of funds raised by the initial public offering of stocks and the time of fund arrival

The company was approved by the China Securities Regulatory Commission's "Reply on the Approval of the Initial Public Offering of Stocks by Zhejiang East Asia Pharmaceutical Co., Ltd." (CSRC License [2020] No. 2814), and the lead underwriter Dongxing Securities Co., Ltd. (hereinafter referred to as the "Sponsor", "Dongxing Securities") passed the Shanghai Stock Exchange system Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Using a combination of offline price inquiry and allotment to qualified investors and online pricing and issuance to public investors holding non-restricted A-shares and non-restricted depositary receipts in the Shanghai market, 28.40 million RMB ordinary shares (A shares) were publicly issued to the public at an issue price of RMB 31.13 per share, and the total amount raised was RMB 884,092,000.00. Yuan, after deducting the brokerage underwriting commission and recommendation fee of 61,438,679.24 yuan (of which the company's basic account has paid 117,924.52 yuan in advance (excluding tax)), the lead underwriter Dongxing Securities on November 20, 2020 On the same day, RMB 822,771,245.28 was remitted into the company's supervision account of the Industrial and Commercial Bank of China Co., Ltd. Sanmen Branch (account number: 1207071129000027135). After deducting additional external costs of RMB 40,214,863.92 related to the issuance of equity securities such as prospectus printing fees, audit fees, lawyer fees, evaluation fees and online issuance fees (of which the company's basic account has paid RMB 1,725,471.70 in advance (excluding tax)), the company's net raised funds this time was RMB 782,438,456.84.

The above-mentioned receipt of funds raised has been verified by Zhonghui Accounting Firm (Special General Partnership), which issued a "Capital Verification Report" (Zhonghui Huiyan [2020] No. 6629) on November 20, 2020. After the raised funds are received, all are deposited in a special account for raised funds opened with the approval of the company's board of directors. The company signed the "Four-Party Supervision Agreement for the Special Account Deposit of Raised Funds" with the sponsor institution Dongxing Securities and the bank where the raised funds are deposited, and implements a special account for depositing the raised funds.

(2) Plans for investment projects using funds raised from initial public offerings of stocks

According to the "East Asia Pharmaceuticals Initial Public Offering Prospectus" disclosed by the company in the designated information disclosure media on November 13, 2020, the net proceeds from the company's initial public offering of stocks after deducting issuance expenses are used to invest in the following projects:

Unit: 10,000 yuan project investment. Planned fundraising serial number. Project name.

Total amount of capital Annual production of key intermediates for cephalosporin drugs 7-ACCA 200 tons,

1 13,690.00 13,690.00 7-ANCA 60-ton technical transformation project

2 The second phase of the cephalosporin API industrial upgrading project with an annual output of 586 tons 47,676.00 47,676.00 3 R&D center construction project 7,624.00 6,877.85 4 Supplementary working capital 10,000.00 10,000.00

Total 78,990.00 78,243.85

(3) Changes in investment projects using funds raised from initial public offerings of stocks

The company held the second session of the board of directors on September 27, 2021 and October 14, 2021. The 17th Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

At the meeting, the 15th meeting of the second board of supervisors and the second extraordinary general meeting of shareholders in 2021, the "Proposal on Changing the Investment Project of Part of the Raised Funds" was reviewed and approved respectively, and it was agreed to change the investment direction of the funds raised in two sub-projects of the "Phase II Project of the Industrial Upgrading Project of Cephalosporin APIs with an annual output of 586 tons", the "200 tons of cefaclor API project with an annual output" and the "30 tons of cefditoren pivoxil API project with an annual output". The total amount of funds raised in this change of investment is 228.70 million yuan, of which 168.70 million yuan will be used to invest in the construction of a "technical transformation project with an annual production capacity of 180 tons of cephalosporin cores and an annual production of 100 tons of oxygen cephalosporin cores", and 60.00 million yuan will be used for additional investment in "an annual production of cephalosporin key intermediates 7-ACCA 200 tons, 7-ANCA 60 tons of technological transformation projects”. The company's independent directors and board of supervisors issued clear opinions on the above matters, and the sponsor issued an agreed verification opinion. For details of the above-mentioned changes in investment projects with part of the raised funds, please refer to the "Announcement of East Asia Pharmaceuticals on Changes in Investment Projects with Partially Raised Funds" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on September 28, 2021 (Announcement No.: 2021-040).

The investment projects with raised funds after the change are as follows:

Unit: 10,000 yuan

Project investment Planned use of fundraising serial number Project name

Total Funding Amount Annual production of 7-ACCA, a key intermediate for cephalosporin drugs, 200 tons,

1 19,690.00 19,690.00 7-ANCA 60-ton technical transformation project

2 The second phase of the industrial upgrading project of cephalosporin raw materials with an annual output of 586 tons 24,806.00 24,806.00 The annual output of cephalosporin core products is 180 tons, and the annual production of oxycephalosporin core products

3 16,870.00 16,870.00 Product 100-ton technical transformation project

4 R&D center construction project 7,624.00 6,877.85 5 Supplementary working capital 10,000.00 10,000.00

Total 78,990.00 78,243.85

2. Management of funds raised from initial public offering of stocks

In accordance with relevant laws and regulations, the company signed a four-party supervision agreement with the sponsor institution and the special account supervision bank for raised funds, opened a special account for raised funds, and implemented special account storage management for raised funds. The company's storage of funds raised from its initial public offering of shares is as follows:

Unit: Bank account opened in 10,000 yuan Bank account number Balance of raised funds Remarks

Agricultural Bank of China Co., Ltd. 19915101040999997-000

Taizhou Huangyan Branch of the Company will be closed in December 2023 0000001

Agricultural Bank of China Co., Ltd. 19915101040999997-000

Account cancellation in December 2023

Co., Ltd. Taizhou Huangyan Branch 0000002

Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Bank of China Co., Ltd.

405245896888 - Sanmen County Branch of the Department for Account Cancellation in December 2023

Industrial and Commercial Bank of China Co., Ltd.

1207071129000027259 - Sanmen Branch of the Co., Ltd. will be closed in September 2022

Industrial and Commercial Bank of China Co., Ltd.

1207071129000027135 - Sanmen Branch of the Company that will be closed in January 2021

Total -

3. Investment status of funds raised from initial public offering of stocks

As of October 30, 2025, all investment projects raised by the company's initial public offering of stocks have been completed. The investment status of the raised funds is as follows:

Unit: 10,000 yuan

Project investment Planned use of raised funds Accumulated funds The project has reached the predetermined serial number Project name

Total amount of capital Amount of total investment Usage status Annual production of cephalosporin drugs Key intermediate

Body 7-ACCA 200 tons,

1 19,690.00 19,690.00 19,894.52 September 2022 7-ANCA 60-ton technical transformation project

Head

Annual output of 586 tons of cephalosporin APIs

2 24,806.00 24,806.00 24,361.35 The second phase of the industrial upgrading project in December 2023

Annual output of cephalosporin core products 180

3 tons, annual production of oxycephalosporin mother core production 16,870.00 16,870.00 16,780.10 Technical transformation project of 100 tons of products in December 2023

4 R&D center construction project 7,624.00 6,877.85 4,491.24 December 5, 2023 Supplementary working capital 10,000.00 10,000.00 10,000.00 -

Total 78,990.00 78,243.85 75,527.21 -

Note: If the total does not match the sum of each addend, it is due to rounding.

The completion of the above-mentioned investment projects and the permanent replenishment of working capital with the remaining raised funds have been reviewed and approved at the 21st meeting of the third board of directors and the 21st meeting of the third board of supervisors held by the company on December 19, 2023. It was agreed that the company's initial public offering of stock investment projects will be completed and the remaining raised funds will be 6,018.41 Ten thousand yuan (including interest fees, etc., the actual amount shall be based on the balance of the special account for raised funds on the day when the funds are transferred out) to permanently supplement working capital for the company's daily production and operations. For details, please refer to the "East Asia Pharmaceuticals Announcement on the Completion of Investment Projects with Funds Raised by the Initial Public Offering of Stocks and the Permanent Replenishment of Liquidity with the Surplus Raised Funds" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on December 20, 2023 (Announcement Number: 2023-083).

Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

4. Project status of this adjustment

The project involved in this adjustment is the R&D center construction project in the company's initial public offering of stock investment project. The amount of raised funds planned to be used for this project is 68.7785 million yuan. As of October 30, 2025, the cumulative amount of raised funds invested in the project is 44.9124 million yuan, and it has reached the scheduled usable status in December 2023.

5. Impact of adjusting the purpose of the R&D center construction project on the company

This adjustment of the purpose of the R&D center construction project in the initial public offering of stock investment project can improve the efficiency of the company's asset use and improve the centralized office efficiency of the company's functional personnel. It will not have a negative impact on the company's economic benefits, will not have a substantial impact on the implementation of the initial public offering of stock investment project, and will not harm the interests of the company and shareholders.

All shareholders and shareholder representatives are invited to consider the above proposals.

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Motion 2:

Regarding investment projects with funds raised from the issuance of convertible corporate bonds to unspecified objects

Proposal to close the project and use the remaining raised funds to permanently replenish working capital

Dear shareholders and shareholder representatives:

Zhejiang East Asia Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") raised funds from the issuance of convertible corporate bonds to unspecified objects in 2023. The investment projects "Characteristic New Drug Preparation R&D and Production Base Construction Project (Phase I)" and "Annual Production of 3,685 tons of pharmaceuticals and intermediates, 4,320 tons of by-product salt project (Phase I)" have all been implemented and have reached the intended use status. In order to further improve the efficiency of the use of raised funds and meet the needs of the company's daily production and operation activities, the company plans to use the remaining raised funds of 147.3234 million yuan (including interest fees, etc., the actual amount is based on the balance of the special account for raised funds on the day the funds are transferred out) to permanently supplement working capital for use in the company's daily production and operations. After the permanent replenishment of working capital is implemented, the unpaid part of the contract balance and warranty deposit will be paid with its own funds when the payment conditions are met. If the actual amount to be paid exceeds the current expected amount to be paid, the company will also make up the amount with its own funds. The specific situation is as follows:

1. The main reasons for the savings in funds raised by issuing convertible corporate bonds to unspecified objects

(1) During the construction and implementation of the convertible bond investment project, the company strictly abides by the relevant regulations on the use of raised funds, and uses the raised funds prudently based on the principles of economy and rationality on the premise of ensuring project quality and controlling implementation risks. The company has improved the efficiency of the use of raised funds by allocating various resources and strengthening the control, supervision and management of costs in all aspects of project construction, including: in the equipment procurement process, funds are rationally utilized by optimizing procurement plans, comparing and screening cost-effective suppliers, etc., thereby saving equipment investment costs; in the project construction process, unnecessary expenditures are reduced by refining construction plans, controlling consumable loss and other means to further reduce the total project investment. Through the above-mentioned various measures, project construction funds have been effectively saved.

(2) During the construction and implementation of the convertible bond investment project, the company received asset-related government subsidy funds, and part of the expenditure on the above-mentioned investment project was paid from the aforementioned government subsidies, reducing the investment of part of the raised funds.

(3) In order to improve the efficiency of the use of raised funds, without affecting the construction of investment projects and the safety of raised funds, the company uses temporarily idle raised funds for cash management to obtain certain financial management income. At the same time, interest income is generated during the storage period of the raised funds, forming a surplus of raised funds.

Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

(4) There are outstanding balances, warranty deposits, and other amounts for projects and equipment that have not yet been paid for the investment projects. The main reason is that the payment cycles for such contract balances and warranty deposits are relatively long. As of now, the payment node has not been reached, and part of the payment has not yet been made.

2. Basic situation of raised funds

(1) Actual amount of funds raised and time of fund arrival

According to the approval of the China Securities Regulatory Commission’s “Reply on the Registration of Zhejiang East Asia Pharmaceutical Co., Ltd.’s Issuance of Convertible Corporate Bonds to Unspecified Objects” (CSRC Permit [2023] No. 1165), the company’s registration application for issuance of convertible corporate bonds to unspecified objects was approved. As of July 12, 2023, the company has issued convertible corporate bonds RMB ordinary shares (A shares) to unspecified objects for RMB 690,000,000 (690,000 lots, 6,900,000 pieces), each with a face value of RMB 100.00, issued at face value, and the bond term is 6 years. The total amount of funds raised by the convertible corporate bonds applied for issuance by the company was RMB 690,000,000. After deducting underwriting fees and other issuance expenses of RMB 9,815,600 (excluding value-added tax), the actual net amount of funds raised was RMB 680,184,400. All the funds raised from this issuance were received on July 12, 2023, and were verified by Zhonghui Accounting Firm (Special General Partnership). A "Verification Report on the Availability of Bond Raised Funds" (Zhonghui Huiyan [2023] No. 8458) was issued on July 12, 2023.

Name of issue Total amount of funds raised by issuing convertible corporate bonds to unspecified objects in 2023 Net amount of funds raised 690.00 million yuan Net amount of funds raised 680.1844 million yuan Time of arrival July 12, 2023

(2) Investment project planning status

According to the "Prospectus for the Issuance of Convertible Corporate Bonds to Unspecified Objects" disclosed by the company in the designated information disclosure media on July 4, 2023, the total amount of funds raised by the company from the issuance of convertible corporate bonds to unspecified objects, after deducting the issuance expenses, is used to invest in the following projects:

Unit: 10,000 yuan project investment Name of project to raise funds

Scale Proposed investment amount Special new pharmaceutical preparation R&D and production base construction project (Phase I) 43,893.00 35,000.00 Annual output of 3,685 tons of pharmaceuticals and intermediates, 4,320 tons of by-product salt project (Phase I) 37,801.00 33,018.44

Total 81,694.00 68,018.44 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

(3) Delay of fundraising projects

The company held the 8th meeting of the 4th Board of Directors and the 7th meeting of the 4th Board of Supervisors on May 30, 2025. They reviewed and approved the "Proposal on the Extension of Investment Projects Raised Funds from Convertible Corporate Bonds" respectively, and agreed to postpone the "Characteristic New Drug Preparation R&D and Production Base Construction Project (Phase I)" and the "Annual Production of 3,685 tons of pharmaceuticals and intermediates and 4,320 tons of by-product salt projects (Phase I)". The company's supervisory board issued a clear agreement on the above matters, and the sponsor issued an agreement on the verification opinion. For details on the extension of the investment project, please refer to the "Announcement on the Extension of the Investment Project with Funds Raised by Convertible Corporate Bonds" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on May 31, 2025 (Announcement No.: 2025-029). The date on which the raised investment project reaches the scheduled usable status will be adjusted. The details are as follows:

The project has reached the scheduled usable status. The project has reached the scheduled usable status. Serial number. Project name.

Date (before adjustment) Date (after adjustment)

Characteristic new pharmaceutical preparation R&D and production base

1 May 2025 December 2025

Land construction project (Phase I)

Annual output of 3,685 tons of pharmaceuticals and intermediates,

2 May 2025 December 2025

4,320 tons of by-product salt project (Phase I)

(4) Management of funds raised by issuing convertible corporate bonds to unspecified objects

In accordance with relevant laws and regulations, the company signed a four-party supervision agreement with the sponsor institution and the special account supervision bank for raised funds, opened a special account for raised funds, and implemented special account storage management for raised funds. As of December 5, 2025, the company's storage status of funds raised from the issuance of convertible corporate bonds to unspecified objects is as follows:

Unit: 10,000 yuan

Bank where the account is opened Bank account number Balance of raised funds Remarks

Bank of China Limited III

400083205788 -Closed in December 2024

Men County Branch

Agricultural Bank of China Co., Ltd. R&D and production of characteristic new pharmaceutical preparations

19950401040099996 466.93

Si Sanmen Coastal Industrial City Branch Industrial Base Construction Project (Phase I) Agricultural Bank of China Co., Ltd.

19915101049876543 -Closed in October 2025

Taizhou Huangyan Branch

China CITIC Bank Co., Ltd. Taiwan has an annual output of 3,685 tons of pharmaceuticals and intermediates,

8110801081539876888 14,265.42

Prefecture Sanmen Branch 4,320 tons of by-product salt project (Phase I)

Total 14,732.34

Note: Any difference in the mantissa between the total and the sum of details is due to unit conversion or rounding.

3. Completion of this fundraising project and savings of raised funds

As of December 5, 2025, the company has raised funds by issuing convertible corporate bonds to unspecified objects. Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

The actual amount of funds used and savings are as follows:

Unit: Financial management income of 10,000 yuan

Commitment of raised funds Actual raised funds and interest received Surplus raised items closed Projects closed

Used amount Used amount Deduction amount Name of fund amount Time

(A) (B) Net after renewal (D=A-B+C)

Amount (C)

Characteristic new drug preparation research

2025

Development and production base construction project 35,000.00 35,248.93 715.85 466.93

December

Project (Phase I)

Annual output of 3,685 tons of pharmaceutical and

2025

Intermediates, 4,320 tons of by-products 33,018.44 19,909.10 1,156.07 14,265.42

December

Salt Project (Phase I)

Total - 68,018.44 55,158.03 1,871.93 14,732.34 Use of surplus raised funds and corresponding funds

Supplementary flow, 147.3234 million yuan

Um ☑

Note 1: The savings from this fundraising project do not include the interest income from bank deposits and cash management income that the company has not yet received. The actual savings amount is based on the balance after bank interest settlement on the day of fund transfer.

Note 2: The remaining amount of this fundraising project includes the contract balance and warranty deposit that have been signed but not yet paid, etc., which may be adjusted due to changes in the final settlement amount. The final amount will be subject to actual payment.

Note 3: The actual amount of raised funds used in the "Special New Drug Preparation R&D and Production Base Construction Project (Phase I)" exceeds the promised use amount of raised funds, because the cumulative investment amount of raised funds includes financial management and interest income.

The impact on the company of permanently replenishing working capital with the remaining funds raised from issuing convertible corporate bonds to unspecified objects

The closing of the raised investment project and the permanent replenishment of working capital with the remaining raised funds is a reasonable arrangement based on the implementation of the raised investment project and the company's own operating conditions. It is conducive to improving the efficiency of the use of raised funds, reducing financial costs, and is in the interests of the company and all shareholders. After implementing the permanent replenishment of working capital, the company will cancel the relevant special account for raised funds, and the four-party supervision agreement for raised funds signed between the company and the sponsor institution and the bank where the raised funds are deposited will be terminated.

The use of surplus raised funds to permanently replenish working capital does not constitute a disguised change in the investment direction of raised funds, and does not violate the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange on the use of raised funds by listed companies.

All shareholders and shareholder representatives are invited to consider the above proposals.

Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Motion 3:

Regarding the cancellation of the company's board of supervisors and the revision of the "Articles of Association"

and handle industrial and commercial registration proposals

Dear shareholders and shareholder representatives:

In accordance with the Company Law of the People's Republic of China (hereinafter referred to as the "Company Law"), the Securities Law of the People's Republic of China, the Guidelines on the Articles of Association of Listed Companies, the Rules of Shareholders' Meetings of Listed Companies, the Stock Listing Rules of the Shanghai Stock Exchange, and the Shanghai Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies. No. 1 - Standardized Operations" and other relevant laws, regulations and normative documents, and based on the actual situation of Zhejiang East Asia Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), the company will cancel the board of supervisors and let the Audit Committee of the Board of Directors exercise the powers of the board of supervisors stipulated in the "Company Law". The company's "Rules of Procedure for the Board of Supervisors" will be abolished accordingly, and the relevant clauses in the "Articles of Association" and the relevant expressions and clauses about supervisors and the board of supervisors in other relevant systems will be revised accordingly. Before the company's general meeting of shareholders considers and approves the cancellation of the board of supervisors, the company's fourth board of supervisors will continue to perform its supervisory functions in strict accordance with relevant laws, regulations and the provisions of the Articles of Association. Safeguard the interests of the company and all shareholders.

The company's board of directors proposed to the shareholders' meeting to authorize the company's board of directors and specific handling personnel to handle industrial and commercial change registration, articles of association filing and other related matters. The revision of the "Articles of Association" will ultimately be subject to the approval of the market supervision and management department.

For details of the "Articles of Association", please refer to the "Announcement on Cancellation of the Board of Supervisors, Amendment of the Articles of Association, and Processing of Industrial and Commercial Registration, Revision and Establishment of Certain Corporate Governance Systems" (Announcement Number: 2025-059) and the full text of the "Articles of Association of Zhejiang East Asia Pharmaceutical Co., Ltd." disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on December 10, 2025.

All shareholders and shareholder representatives are invited to consider the above proposals.

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Motion 4.00:

Proposal on amending and formulating some corporate governance systems

Dear shareholders and shareholder representatives:

In order to implement the latest laws and regulations, further improve the corporate governance structure of Zhejiang East Asia Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), and improve the company's standard operation level, in accordance with the latest relevant provisions of the "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies", "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Self-Regulatory Supervision Guidelines No. 1 - Standardized Operations" and other laws, regulations and normative documents, and in light of the company's actual situation, the company plans to revise and formulate some governance systems. Among them, the following systems still need to be submitted to the company's shareholders' meeting for review. The details are as follows:

Is stock serial number required? System name type

Deliberation of the General Meeting 01 Rules of Procedure for the General Meeting of Shareholders Revised Yes 02 Rules of Procedure for the Board of Directors Revised Yes 03 External Guarantee Management System Revised Yes 04 Related Party Transaction Decision-making System Revised Yes 05 Raised Fund Management System Revised Yes 06 Working System of Independent Directors Revised Yes 07 Implementation Rules of the Cumulative Voting System Revised Yes 08 Investment Decision Management System Revised Yes 09 Prevent Controlling Shareholders, Actual Controllers and Related Parties from Occupying the Company’s Fund Management System Revised Yes 10 Remuneration management system for directors, supervisors and senior managers Revised Yes 11 Accounting firm selection and appointment system Revised Yes 12 Implementation rules for online voting of shareholders’ meetings Formulated Yes

Bill 4.01:

Proposal on Amending the Company’s Rules of Procedure for the General Meeting of Shareholders

Dear shareholders and shareholder representatives:

In order to implement the latest laws and regulations, further improve the company's corporate governance structure, and improve the company's standard operation level, in accordance with the latest "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies", "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Listed Companies Self-Regulatory Guidelines No. 1 - Standardized Operation" and other relevant provisions of laws, regulations and normative documents, and in combination with the actual situation of the company, Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

According to the situation, the company plans to amend some provisions of the "Rules of Procedure for the General Meeting of Shareholders".

For details, please refer to the full text of the "Rules of Procedure for the Shareholders' Meeting" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on December 10, 2025.

All shareholders and shareholder representatives are invited to consider the above proposals.

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Bill 4.02:

Proposal on Amending the Company’s Rules of Procedure for the Board of Directors

Dear shareholders and shareholder representatives:

In order to implement the latest laws and regulations, further improve the company's corporate governance structure, and improve the company's standard operation level, in accordance with the latest relevant provisions of laws, regulations, normative documents such as the latest "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies", "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Listed Companies Self-Regulatory Guidelines No. 1 - Standardized Operations", and in light of the company's actual situation, the company plans to revise some provisions of the "Board of Directors Rules of Procedure".

For details, please refer to the full text of the "Rules of Procedure of the Board of Directors" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on December 10, 2025.

All shareholders and shareholder representatives are invited to consider the above proposals.

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Motion 4.03:

Proposal on Amending the Company's "External Guarantee Management System"

Dear shareholders and shareholder representatives:

In order to implement the latest laws and regulations, further improve the company's corporate governance structure, and improve the company's standard operation level, in accordance with the latest relevant provisions of laws, regulations, normative documents such as the latest "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies", "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Listed Companies Self-Regulatory Guidelines No. 1 - Standardized Operations", and in light of the company's actual situation, the company plans to revise some provisions of the "External Guarantee Management System".

For details, please refer to the full text of the "External Guarantee Management System" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on December 10, 2025.

All shareholders and shareholder representatives are invited to consider the above proposals.

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Bill 4.04:

Proposal on Amending the Company’s “Related Transaction Decision-making System”

Dear shareholders and shareholder representatives:

In order to implement the latest laws and regulations, further improve the company's corporate governance structure, and improve the company's standard operation level, in accordance with the latest relevant provisions of laws, regulations, normative documents such as the "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies", "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Listed Companies Self-Regulatory Guidelines No. 1 - Standardized Operations", and in light of the company's actual situation, the company plans to revise some provisions of the "Related Transaction Decision-making System".

For details, please refer to the full text of the "Related Transaction Decision-making System" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on December 10, 2025.

All shareholders and shareholder representatives are invited to consider the above proposals.

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Motion 4.05:

Proposal on Amending the Company's "Raised Funds Management System"

Dear shareholders and shareholder representatives:

In order to implement the latest laws and regulations, further improve the company's corporate governance structure, and improve the company's standard operation level, in accordance with the latest relevant provisions of laws, regulations, normative documents such as the "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies", "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Listed Companies Self-Regulatory Guidelines No. 1 - Standardized Operations", and in light of the company's actual situation, the company plans to revise some provisions of the "Raised Funds Management System".

For details, please refer to the full text of the "Raised Funds Management System" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on December 10, 2025.

All shareholders and shareholder representatives are invited to consider the above proposals.

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Motion 4.06:

Proposal on Amending the Company's "Working System for Independent Directors"

Dear shareholders and shareholder representatives:

In order to implement the latest laws and regulations, further improve the company's corporate governance structure, and improve the company's standard operation level, in accordance with the latest relevant provisions of laws, regulations, normative documents such as the "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies", "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Listed Companies Self-Regulatory Guidelines No. 1 - Standardized Operations", and in light of the company's actual situation, the company plans to revise some provisions of the "Independent Director Work System".

For details, please refer to the full text of the "Independent Directors' Working System" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on December 10, 2025.

All shareholders and shareholder representatives are invited to consider the above proposals.

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Motion 4.07:

Proposal on amending the company's "Implementation Rules of Cumulative Voting System"

Dear shareholders and shareholder representatives:

In order to implement the latest laws and regulations, further improve the company's corporate governance structure, and improve the company's standard operation level, in accordance with the latest relevant provisions of laws, regulations and normative documents such as the "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies", "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Listed Companies Self-Regulatory Guidelines No. 1 - Standardized Operations", and in light of the company's actual situation, the company plans to revise some provisions of the "Cumulative Voting System Implementation Rules".

For details, please refer to the full text of the "Cumulative Voting System Implementation Rules" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on December 10, 2025.

All shareholders and shareholder representatives are invited to consider the above proposals.

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Motion 4.08:

Proposal on amending the company's "Investment Decision Management System"

Dear shareholders and shareholder representatives:

In order to implement the latest laws and regulations, further improve the company's corporate governance structure, and improve the company's standard operation level, in accordance with the latest relevant provisions of laws, regulations, normative documents such as the latest "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies", "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Listed Companies Self-Regulatory Guidelines No. 1 - Standardized Operations", and in light of the company's actual situation, the company plans to revise some provisions of the "Investment Decision Management System".

For details, please refer to the full text of the "Investment Decision Management System" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on December 10, 2025.

All shareholders and shareholder representatives are invited to consider the above proposals.

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Motion 4.09:

Regarding the revision of the company's "Preventing Controlling Shareholders, Actual Controllers and Related Parties from Occupying Public Property"

Proposal on "Divisional Fund Management System"

Dear shareholders and shareholder representatives:

In order to implement the latest legal and regulatory requirements, further improve the company's corporate governance structure, and improve the company's standard operation level, in accordance with the relevant provisions of the latest laws, regulations and normative documents such as the "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies", "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 1 - Standardized Operations", and in light of the company's actual situation, the company plans to revise some provisions of the "Prevent Controlling Shareholders, Actual Controllers and Related Parties from Occupying the Company's Fund Management System".

For details, please refer to the full text of the "Management System to Prevent Controlling Shareholders, Actual Controllers and Related Parties from Occupying the Company's Funds" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on December 10, 2025.

All shareholders and shareholder representatives are invited to consider the above proposals.

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Motion 4.10:

Regarding the revision of the company's "Remuneration Management System for Directors, Supervisors and Senior Management Personnel"

motion

Dear shareholders and shareholder representatives:

In order to implement the latest laws and regulations, further improve the company's corporate governance structure, and improve the company's standard operation level, in accordance with the latest relevant provisions of laws, regulations, normative documents such as the "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies", "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Listed Companies Self-Regulatory Guidelines No. 1 - Standardized Operation", and in light of the company's actual situation, the company plans to revise some provisions of the "Remuneration Management System for Directors, Supervisors and Senior Managers".

For details, please refer to the full text of the "Remuneration Management System for Directors and Senior Management" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on December 10, 2025.

All shareholders and shareholder representatives are invited to consider the above proposals.

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Motion 4.11:

Proposal on Amending the Company's "Accounting Firm Selection and Recruitment System"

Dear shareholders and shareholder representatives:

In order to implement the latest laws and regulations, further improve the company's corporate governance structure, and improve the company's standard operation level, in accordance with the latest relevant provisions of laws, regulations, normative documents such as the "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies", "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Listed Companies Self-Regulatory Guidelines No. 1 - Standardized Operations", and in light of the company's actual situation, the company plans to revise some provisions of the "Accounting Firm Selection System".

Please see the attachment for details.

All shareholders and shareholder representatives are invited to consider the above proposals.

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Attachment: "Selection and Recruitment System of Accounting Firm of Zhejiang East Asia Pharmaceutical Co., Ltd."

Zhejiang East Asia Pharmaceutical Co., Ltd.

Accounting firm selection system

Chapter 1 General Provisions

Article 1 In order to regulate the selection (including renewal and re-appointment) of accounting firms by Zhejiang East Asia Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), effectively protect the interests of shareholders, and improve the quality of financial information, in accordance with the "Company Law of the People's Republic of China" and the "Securities Law of the People's Republic of China" This system is formulated based on the provisions of the "Measures for the Management of the Selection of Accounting Firms by State-owned Enterprises and Listed Companies" and other relevant laws, regulations, normative documents and the "Articles of Association of Zhejiang East Asia Pharmaceutical Co., Ltd." (hereinafter referred to as the "Articles of Association"), taking into account the actual situation of the company.

Article 2 The term “selection of accounting firms” as used in this system refers to the act of a company appointing an accounting firm to issue audit opinions and issue audit reports on financial accounting reports in accordance with the requirements of relevant laws and regulations.

Article 3 If a company appoints an accounting firm to engage in other statutory audit services other than the audit of financial accounting reports, it may refer to this system.

Article 4 When a company hires or dismisses an accounting firm, it shall be reviewed and approved by the audit committee, submitted to the board of directors for review, and decided by the shareholders' meeting. The company shall not hire an accounting firm to carry out audit work before the board of directors and shareholders meeting review.

Chapter 2 Requirements for the Practice Quality of Accounting Firms

Article 5 The accounting firm selected by the company shall meet the following conditions:

(1) Have independent subject qualifications and have the qualifications to carry out securities futures business as stipulated by the national industry authorities and the China Securities Regulatory Commission (hereinafter referred to as the “China Securities Regulatory Commission”);

Qualifications required for cargo-related business;

Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

(2) Have a fixed workplace, a sound organizational structure and complete internal management and

control system;

(3) Be familiar with national laws, regulations, rules and policies related to financial accounting;

(4) Certified public accountants with the qualifications to complete audit tasks and ensure audit quality;

(5) Earnestly implement laws, regulations, rules and policies related to financial auditing, and

Have a good social reputation and practice quality record;

(6) Other conditions specified by the China Securities Regulatory Commission.

Chapter 3 Procedures for Selection of Accounting Firms

Article 6 When selecting an accounting firm, a company shall use competitive negotiation, public bidding, invitational bidding, and other selection methods that can fully understand the accounting firm's competency to ensure that the selection work is conducted fairly and impartially.

Article 7 If public selection methods such as competitive negotiation, public bidding, invitational bidding, etc. are adopted, the selection documents shall be released through public channels such as the company's official website. The selection documents shall include basic selection information, evaluation factors, specific scoring standards, etc. The company shall determine the response time for the accounting firm to submit application documents after the selection documents are released in accordance with the law, and ensure that the accounting firm has sufficient time to obtain selection information and prepare application materials. Companies may not restrict or exclude potential accounting firms with unreasonable conditions, and may not tailor selection conditions for individual accounting firms. The selection results shall be announced in a timely manner, and the disclosure content shall include the accounting firm to be selected and the audit fees.

The company should evaluate and score each valid application document individually and summarize the scores for each evaluation factor. Among them, the score weight of quality management level should not be less than 40%, and the score weight of audit fee quotation should not be higher than 15%. The company should record and save the evaluation opinions of the participating evaluation personnel.

Article 8 The Audit Committee is responsible for selecting an accounting firm and supervising the performance of its audit work. The audit committee shall effectively perform the following responsibilities:

(1) Formulate policies, procedures and relevant procedures for selecting accounting firms in accordance with the authorization of the board of directors

Regarding internal control systems;

Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

(2) Propose to start the work related to selecting an accounting firm;

(3) Review the selection documents, determine the evaluation elements and specific scoring standards, and supervise the selection process

process;

(4) Propose recommendations on the selection of accounting firms and audit fees, and submit them to the decision-making body

decide;

(5) Supervise and evaluate the audit work of accounting firms;

(6) Submit to the board of directors regularly (at least every year) the performance of the hired accounting firm

Situation assessment report and report on the performance of supervisory responsibilities by the audit committee;

(7) Responsible for the selection of accounting firms authorized by laws, regulations, articles of association and the board of directors

other matters.

The evaluation factors for selecting an accounting firm should at least include the audit fee quotation, the accounting firm's qualifications, practice records, quality management level, work plan, human and other resource allocation, information security management, risk-taking ability level, etc.

Article 9 The audit committee shall be highly cautious and pay attention to the following situations:

(1) The accounting firm is changed from the balance sheet date to the issuance of the annual report, the accounting firm is changed for two consecutive years, or the accounting firm is changed multiple times in the same year;

firm;

(2) The accounting firm to be hired has been subject to multiple administrative penalties or penalties due to its quality of practice in the past three years.

Several audit projects are currently under investigation;

(3) The original audit team is planned to be transferred to another accounting firm;

(4) The audit fees during the appointment period have changed significantly compared with the previous year, or the cost of the appointment has changed significantly.

The transaction price is significantly lower than the benchmark price;

(5) The accounting firm failed to substantially rotate audit project partners and sign notes as required

Certified Public Accountant.

Article 10 The basic procedures for selecting an accounting firm are:

(1) The Audit Committee proposes to select an accounting firm for relevant work, and the company’s financial

The department cooperates with preliminary preparation, investigation, data collection and other related work;

(2) The accounting firm participating in the selection shall submit relevant information to the Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders within the specified time.

The Finance Department will conduct a preliminary review and collation, form a written report and submit it to the Audit Committee;

(3) The audit committee shall review the qualifications of accounting firms participating in the competition;

(4) After review and approval by the Audit Committee, the accounting firm responsible for the audit matters will be selected.

and report to the board of directors;

(5) After review and approval by the board of directors, it will be reported to the company’s shareholders’ meeting for approval, and the company will promptly perform information disclosure

obligation to disclose;

(6) According to the resolution of the shareholders' meeting, the company signs an appointment agreement with the accounting firm.

Article 11 The company shall strengthen the review of the information security management capabilities of the accounting firm when recruiting, set up separate clauses in the employment agreement to clarify the information security protection responsibilities and requirements, strengthen the control of confidential and sensitive information when providing documents and materials to the accounting firm, and effectively prevent the risk of information leakage. Accounting firms should fulfill their information security protection obligations and regulate information and data processing activities in accordance with laws, regulations and contracts.

Article 12 The hired accounting firm shall perform its obligations in accordance with the provisions of the relevant business agreement and complete the audit business within the specified time.

Article 13 The company and the hired accounting firm shall properly archive and preserve the selection, application, review, employment documents and relevant decision-making materials, and shall not forge, alter, conceal or destroy them. The retention period of documents and data is at least 10 years from the date of completion of recruitment.

Chapter 4 Procedures for Changing Accounting Firms

Article 14 When a company dismisses or does not renew the appointment of an accounting firm, it shall notify the accounting firm 30 days in advance.

Article 15 If a company changes its accounting firm, it shall complete the selection process before the end of the fourth quarter of the year being audited.

Article 16 When reviewing the proposal for changing the appointment of an accounting firm, the audit committee may interview the predecessor and the accounting firm to be hired, carefully investigate the practice quality and integrity of the accounting firm to be hired, make a reasonable evaluation of the practice quality of both parties, and issue an audit opinion based on its judgment on the adequacy of the reasons for the change. The Audit Committee reviewed and approved the changes to the meeting materials of the first extraordinary general meeting of shareholders of Zhejiang East Asia Pharmaceutical Co., Ltd. in 2025

If an accounting firm is hired, the accounting firm to be hired shall be selected in accordance with the procedures for selecting an accounting firm.

Article 17 After the board of directors considers and approves the proposal to re-appoint an accounting firm, it shall issue a notice of the shareholders' meeting. The former accounting firm can state its opinions at the shareholders' meeting, and the company's board of directors should provide convenient conditions for the former accounting firm to state its opinions at the shareholders' meeting.

Article 18 Unless there are major deficiencies in the quality of the accounting firm's practice, the auditors and time schedule are difficult to ensure that the company discloses the annual report on time, or the accounting firm requests to terminate the company's audit business, the company shall not change the accounting firm to perform the annual report audit business during the annual report audit period.

Article 19 If a company plans to re-appoint an accounting firm, it may disclose the reasons for dismissal of the accounting firm, the opinions of the audit committee, the communication status of the previous accounting firm, etc. in the announcement of the replacement of the accounting firm.

Article 20 If an accounting firm voluntarily requests to terminate the company's audit business, the audit committee shall learn the reasons in detail from the relevant accounting firm and make a written report to the board of directors. The accounting firm shall explain to the shareholders' meeting whether there is any misconduct in the company. The company carries out the re-employment procedures in accordance with the above regulations.

Chapter 5 Information Disclosure, Supervision and Punishment

Article 21 The company shall disclose the service years, audit fees and other information of the accounting firm, audit project partners, and signing certified public accountants in the annual final financial report or annual report.

Article 22 The company shall disclose as required every year an evaluation report on the performance of the accounting firm's duties and a report on the audit committee's performance of supervisory responsibilities over the accounting firm. If a change of accounting firm is involved, the company shall also disclose the status of the predecessor accounting firm and the audit opinions of the previous year, the reasons for the change of accounting firm, the communication status with the predecessor accounting firm, etc.

Article 23 The audit committee shall urge the external audit institution to be honest, trustworthy, diligent and responsible, strictly abide by business rules and industry self-discipline norms, strictly implement the internal control system, and review the company's financial affairs Zhejiang Dongya Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Verify and verify accounting reports, perform special attention obligations, and prudently express professional opinions.

Article 24 If an accounting firm undertaking auditing services commits any of the following acts and the circumstances are serious, upon resolution of the shareholders' meeting, the company will no longer select it to undertake auditing work:

(1) Subcontract or subcontract the audit projects undertaken to other institutions;

(2) The audit report does not meet the audit work requirements and there are obvious audit quality problems.

Chapter 6 Supplementary Provisions

Article 25 Matters not covered by this system shall be implemented in accordance with the provisions of relevant laws, administrative regulations, normative documents and the Articles of Association. If this system is inconsistent with relevant laws, administrative regulations, normative documents and the relevant provisions of the Articles of Association, the laws, administrative regulations, normative documents and the "Articles of Association" shall be

The provisions of the Articles of Association shall prevail.

Article 26 This system shall be formulated and interpreted by the board of directors. It shall take effect after being reviewed and approved by the company's board of directors and submitted to the company's shareholders' meeting for approval. The same applies to modifications.

Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025 Zhejiang East Asia Pharmaceutical Co., Ltd. 2025 First Extraordinary General Meeting of Shareholders Meeting Materials

Motion 4.12:

Proposal on formulating the company's "Implementation Rules for Online Voting of Shareholders' Meetings"

Dear shareholders and shareholder representatives:

In order to implement the latest laws and regulations, further improve the company's corporate governance structure, and improve the company's standard operation level, in accordance with the latest relevant provisions of laws, regulations, and normative documents such as the latest "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies", "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Listed Companies Self-Discipline Supervision Guidelines No. 1 - Standardized Operations", and in combination with the company's actual situation, the company plans to formulate the "Implementation Rules for Online Voting of Shareholders' Meetings".

For details, please refer to the full text of the "Implementation Rules for Online Voting of Shareholders' Meetings" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on December 10, 2025.

All shareholders and shareholder representatives are invited to consider the above proposals.

Board of Directors of Zhejiang East Asia Pharmaceutical Co., Ltd.

December 25, 2025